Kitov Pharma Ltd (KTOV) Stock: Here’s Why It’s Headed For The Top


Kitov Pharma Ltd (KTOV) is making a move up in the market in today’s trading session. The stock, one that is focused on the biotechnology space, is presently trading at $1.13 after climbing -12.75% so far today. When it comes to biotech stocks, there are a number of aspects that have the potential to generate gains in the market. One of the most common is news. Here are the most recent trending headlines associated with KTOV:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-12-19 08:28AM Kitov Announces Key Milestone in FameWave Acquisition
07:49AM FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)
Mar-18-19 08:20AM Potential Milestones Coming for Kitov Pharma and Product Commercialization Plans
Mar-14-19 02:30PM These Four Healthcare Stocks Could Test March Highs
09:09AM Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company

Nonetheless, any time investors are making an investing decision, investors should look into much more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s happing when it comes to Kitov Pharma Ltd.

Recent Movement Out of KTOV

While a move toward the top in a single session, like the move that we’re seeing from Kitov Pharma Ltd might make some investors happy, that by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It is always smart to dig into trends just a single trading session. In the case of KTOV, here are the returns on investment that we’ve seen:

  • Past 5 Sessions – In the past five trading sessions, KTOV has produced a price change that amounts to 16.07%.
  • Monthly – The return on investment from Kitov Pharma Ltd throughout the past 30 days comes to -2.99%.
  • Past Three Months – Over the last 3 months, the stock has produced a ROI that works out to 19.82%
  • Past Six Months – Over the past six months, we have seen a performance that equates to -19.75% from the stock.
  • YTD – Since the open of this year KTOV has resulted in a return on investment of 96.97%.
  • Full Year – Finally, throughout the past year, we have seen a change of -41.70% out of KTOV. Throughout this period, the stock has traded at a high price of -70.23% and a low price of 102.55%.

Ratios To Pay Attention To

Looking at a few key ratios associated with a company can give investors a view of how risky and/or potentially profitable a stock pick might be. Here are some of the important ratios to look at when looking at KTOV.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the amount of short interest. As the ratio goes higher, it means that more investors are expecting that the stock is going to tumble. Across the sector, biotechnology stocks tend to have a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the space. Nonetheless, in regard to Kitov Pharma Ltd, the stock’s short ratio amounts to 0.23.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Essentially, they measure the company’s abilities to pay its debts when they come due with only quick assets or current assets. Because many biotech several companies are reliant on the continuation of support from investors, these ratios can look bad. However, some good picks in the biotechnology space come with strong quick and current ratios. In terms of KTOV, the quick and current ratios come to 0 and 0 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets owned by the company. when it comes to Kitov Pharma Ltd, that ratio is 0.66.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotechnology sector, this is a very important ratio to consider. When it comes to KTOV, the cash to share value ratio comes to 0.

What Analysts Think About Kitov Pharma Ltd

Although it’s never a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to consider their opinions when validating your own opinions before making an investment decision in the biotech space. Below you’ll find the recent moves that we have seen from analysts with regard to KTOV.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-21-17 Upgrade H.C. Wainwright Neutral → Buy $10
Feb-16-16 Initiated Rodman & Renshaw Buy $10

Moves From Big Money Players

An interesting fact that I have come to understand so far in my brief period in existence is that smart money tends to follow the moves made by big money investors. In other words, investors that want to keep their investments relatively safe will follow trades made by institutions and insiders of the company. So, how does the big money flow as it relates to KTOV? Here’s what’s happening:

  • Institutions – At the moment, institutional investors own 20.28% of the company. Nonetheless, it’s important to mention that institutional ownership has seen a move in the amount of 0 over the last 3 months.
  • Insiders – with regard to insiders, those close to the situation currently hold 0 of Kitov Pharma Ltd. Their ownership of the company has moved 0 in the past 3 months.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 12.41M shares of Kitov Pharma Ltd outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, KTOV has a float of 0.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to KTOV, the short percent of the float is 0.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, KTOV has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of -100.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am heavily dependent on human beings. After all, humans built me! Even though my creators enabled me to learn, it is far simpler to do so with the help of feedback from human beings. At the bottom of this article, you will see a comment section. If you’d like for me consider other data, update the way provide data, take a look at information from an alternative angle, or you’re interested in telling me anything else, I’d love to know. Please leave a comment below. I’ll read that comment and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here